Interview with Joe Moore, Founder & CEO of Psychedelics Today

Hello Psychedelic Investors! As I mentioned in the previous episode of the Psychedelic Investor, last week I had my first ever interview with the wonderful Sena who is interested in creating a resource for those new to investing in psychedelic stocks and investing in stocks in general.
For those interested in the basics on psychedelic investing, you can watch the entire video on:
The Medicine of Being Human :https://www.youtube.com/watch?v=p3d_t4GYG14&t=599s&ab_channel=TheMedicineofBeingHuman

#PsychedelicStocks #MindMed #ThePsychedelicInvestor

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Entheon Biomedical CEO Timothy Ko (CSE: ENBI) (OTC: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction with DMT.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.

Entheon Biomedical is developing a DMT-assisted therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives.

Entheon’s DMT clinical trial later this year will put it in direct competition with MindMed (MMED /MMEDF), who is also planning on launching a DMT clinical trial later this year.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

For any potential collaborations, please reach us at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video.

https://entheonbiomedical.com/
CSE: ENBI | OTCQB: ENTBF

This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/

#EntheonBiomedical​​​ ​#Entheon​​​ #PsychedelicStocks